/
Oncology
Acute Lymphoblastic Leukemia
175
Pipeline Programs↗
260
Active Trials↗
102
Companies Involved↗
Acute Lymphoblastic Leukemia is a highly competitive landscape with 175 programs across 102 companies. The most active players are Chongqing Precision Biotech Co., Ltd, Sichuan Baili Pharmaceutical Co., Ltd., Actinium Pharmaceuticals. 39 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical49
Phase 144
Phase 243
Phase 339
Approved
No programs
Analysis
Modality Breakdown
61%
Small molecule
89 of 147 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 147 classified programs, each share of the total. Modality classified for 93% of 175 pipeline programs.
Analysis
Trial Status
849
clinical trials
Completed365 · 43%
Recruiting151 · 18%
Terminated99 · 12%
Unknown status82 · 10%
Active, not recruiting76 · 9%
Withdrawn32 · 4%
Other44 · 5%
Clinical Trials
Trial Activity
849 trials
Page 1 of 57
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)